Sunday, April 18, 2021

Coronavirus | Serum Institute says reports of Covishield vaccine availability in 73 days false

Coronavirus | Serum Institute says reports of Covishield vaccine availability in 73 days false

It would be commercialised once the trials are proven successful , it says.

The city-based Serum Institute of India (SII) on Sunday clarified that claims in the media regarding its COVID-19 vaccine Covishield’s availability in 73 days are completely ‘false’ and ‘conjectural’.

Full coverage on coronavirus

There were reports in certain sections in the media claiming that the SII would be able to commercialise its vaccine, which is being developed by AstraZeneca and Oxford University, in the next 73 days.

“The SII would like to clarify that the current claims surrounding Covishield’s availability in the media are completely false and conjectural. Presently, the government has granted us permission to only manufacture the vaccine and stockpile it for future use,” read a statement issued by the company.

It said the Covishield would be commercialised once the trials were proven successful and all the requisite regulatory approvals were in place.

Also read: If everything goes well India would get COVID-19 vaccine by year-end: Harsh Vardhan

“The phase-3 trials for the Oxford-AstraZeneca vaccine are still under way. And only once the vaccine is proven immunogenic and efficacious, SII will confirm its availability, officially,” it said.

With the trials of the Covishield vaccine showing encouraging results, Adar Poonawalla, CEO of the Serum Institute of India (SII), had earlier said at least 300 million doses would be ready by December.

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Faster pages

Move smoothly between articles as our pages load instantly.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.


A one-stop-shop for seeing the latest updates, and managing your preferences.

Personalised recommendations

A select list of articles that match your interests and tastes.


We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Source link

Leave a Response